Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4175408 in Advanced Solid Tumors
NCT07046923Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2025
- Primary completion
- Jul 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 6
01
Overview
Phase 1, open-label trial of LY4175408 in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), endometrial cancer (EC) and 1 more (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with Dose Limiting Toxicities at 21 days and Overall Response Rate up to 4 years. Started Jul 2025; status: recruiting.
02
Drugs
LY4175408
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)endometrial cancer (EC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07046923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07046923.